127 related articles for article (PubMed ID: 34100390)
21. Loss of PTEN expression in breast cancer: association with clinicopathological characteristics and prognosis.
Li S; Shen Y; Wang M; Yang J; Lv M; Li P; Chen Z; Yang J
Oncotarget; 2017 May; 8(19):32043-32054. PubMed ID: 28410191
[TBL] [Abstract][Full Text] [Related]
22. Role of HER3 expression and PTEN loss in patients with HER2-overexpressing metastatic breast cancer (MBC) who received taxane plus trastuzumab treatment.
Park YH; Jung HA; Choi MK; Chang W; Choi YL; Do IG; Ahn JS; Im YH
Br J Cancer; 2014 Jan; 110(2):384-91. PubMed ID: 24346286
[TBL] [Abstract][Full Text] [Related]
23. Prognostic tissue biomarker exploration for patients with metastatic renal cell carcinoma receiving vascular endothelial growth factor receptor tyrosine kinase inhibitors.
Park I; Cho YM; Lee JL; Ahn JH; Lee DH
Tumour Biol; 2016 Apr; 37(4):4919-27. PubMed ID: 26526582
[TBL] [Abstract][Full Text] [Related]
24. The prognostic value and potential drug target of phosphatase and tensin homolog in breast cancer patients: A meta-analysis.
Xu F; Zhang C; Cui J; Liu J; Li J; Jiang H
Medicine (Baltimore); 2017 Sep; 96(36):e8000. PubMed ID: 28885360
[TBL] [Abstract][Full Text] [Related]
25. Compound Genomic Alterations of TP53, PTEN, and RB1 Tumor Suppressors in Localized and Metastatic Prostate Cancer.
Hamid AA; Gray KP; Shaw G; MacConaill LE; Evan C; Bernard B; Loda M; Corcoran NM; Van Allen EM; Choudhury AD; Sweeney CJ
Eur Urol; 2019 Jul; 76(1):89-97. PubMed ID: 30553611
[TBL] [Abstract][Full Text] [Related]
26. Clinical Characterization of Low Prostate-specific Antigen on Prognosis in Patients With Metastatic Castration-naive Prostate Cancer.
Kodama H; Hatakeyama S; Narita S; Takahashi M; Sakurai T; Kawamura S; Hoshi S; Ishida M; Kawaguchi T; Ishidoya S; Shimoda J; Narita T; Sato H; Mitsuzuka K; Tochigi T; Tsuchiya N; Arai Y; Habuchi T; Ohyama C
Clin Genitourin Cancer; 2019 Dec; 17(6):e1091-e1098. PubMed ID: 31575477
[TBL] [Abstract][Full Text] [Related]
27. Phosphatase and tensin homolog expression related to cetuximab effects in colorectal cancer patients: a meta-analysis.
Shen Y; Yang J; Xu Z; Gu DY; Chen JF
World J Gastroenterol; 2012 Jun; 18(21):2712-8. PubMed ID: 22690082
[TBL] [Abstract][Full Text] [Related]
28. Loss of Expression of PTEN is Associated with Worse Prognosis in Patients with Cancer.
Qiu ZX; Zhao S; Li L; Li WM
Asian Pac J Cancer Prev; 2015; 16(11):4691-8. PubMed ID: 26107225
[TBL] [Abstract][Full Text] [Related]
29. Association between PTEN and clinical-pathological features of osteosarcoma.
Zhou J; Xiao X; Wang W; Luo Y
Biosci Rep; 2019 Jul; 39(7):. PubMed ID: 31270249
[TBL] [Abstract][Full Text] [Related]
30. p53 status in the primary tumor predicts efficacy of subsequent abiraterone and enzalutamide in castration-resistant prostate cancer.
Maughan BL; Guedes LB; Boucher K; Rajoria G; Liu Z; Klimek S; Zoino R; Antonarakis ES; Lotan TL
Prostate Cancer Prostatic Dis; 2018 Jun; 21(2):260-268. PubMed ID: 29302046
[TBL] [Abstract][Full Text] [Related]
31. Prognostic Value of Germline DNA Repair Gene Mutations in De Novo Metastatic and Castration-Sensitive Prostate Cancer.
Wei Y; Wu J; Gu W; Wang J; Lin G; Qin X; Dai B; Gan H; Ye D; Zhu Y
Oncologist; 2020 Jul; 25(7):e1042-e1050. PubMed ID: 32190957
[TBL] [Abstract][Full Text] [Related]
32. Loss of PTEN Expression Is Associated With High MicroRNA 24 Level and Poor Prognosis in Patients With Tongue Squamous Cell Carcinoma.
Zhao J; Chi J; Gao M; Zhi J; Li Y; Zheng X
J Oral Maxillofac Surg; 2017 Jul; 75(7):1449.e1-1449.e8. PubMed ID: 28413152
[TBL] [Abstract][Full Text] [Related]
33. Quantitative Multiparametric MRI Features and PTEN Expression of Peripheral Zone Prostate Cancer: A Pilot Study.
McCann SM; Jiang Y; Fan X; Wang J; Antic T; Prior F; VanderWeele D; Oto A
AJR Am J Roentgenol; 2016 Mar; 206(3):559-65. PubMed ID: 26901012
[TBL] [Abstract][Full Text] [Related]
34. PTEN Loss in a Prostate Cancer Cohort From Jordan.
Al Bashir S; Alzoubi A; Alfaqih MA; Kheirallah K; Smairat A; Haddad H; Al-Dwairy A; Fawwaz BAB; Alzoubi M; Trpkov K
Appl Immunohistochem Mol Morphol; 2020; 28(5):389-394. PubMed ID: 30614821
[TBL] [Abstract][Full Text] [Related]
35. Prognostic value of ERG, PTEN, CRISP3 and SPINK1 in predicting biochemical recurrence in prostate cancer.
Noh BJ; Sung JY; Kim YW; Chang SG; Park YK
Oncol Lett; 2016 Jun; 11(6):3621-3630. PubMed ID: 27284364
[TBL] [Abstract][Full Text] [Related]
36. PTEN gene expression and mutations in the PIK3CA gene as predictors of clinical benefit to anti-epidermal growth factor receptor antibody therapy in patients with KRAS wild-type metastatic colorectal cancer.
Sood A; McClain D; Maitra R; Basu-Mallick A; Seetharam R; Kaubisch A; Rajdev L; Mariadason JM; Tanaka K; Goel S
Clin Colorectal Cancer; 2012 Jun; 11(2):143-50. PubMed ID: 22285706
[TBL] [Abstract][Full Text] [Related]
37. Analysis of PTEN, BRAF and PI3K status for determination of benefit from cetuximab therapy in metastatic colorectal cancer patients refractory to chemotherapy with wild-type KRAS.
Tural D; Batur S; Erdamar S; Akar E; Kepil N; Mandel NM; Serdengeçti S
Tumour Biol; 2014 Feb; 35(2):1041-9. PubMed ID: 23996432
[TBL] [Abstract][Full Text] [Related]
38. Risk Stratification of Prostate Cancer Through Quantitative Assessment of PTEN Loss (qPTEN).
Jamaspishvili T; Patel PG; Niu Y; Vidotto T; Caven I; Livergant R; Fu W; Kawashima A; How N; Okello JB; Guedes LB; Ouellet V; Picanço C; Koti M; Reis RB; Saad F; Mes-Masson AM; Lotan TL; Squire JA; Peng YP; Siemens DR; Berman DM
J Natl Cancer Inst; 2020 Nov; 112(11):1098-1104. PubMed ID: 32129857
[TBL] [Abstract][Full Text] [Related]
39. Combined loss of TFF3 and PTEN is associated with lethal outcome and overall survival in men with prostate cancer.
Abou-Ouf H; Ghosh S; Box A; Palanisamy N; Bismar TA
J Cancer Res Clin Oncol; 2019 Jul; 145(7):1751-1759. PubMed ID: 31129769
[TBL] [Abstract][Full Text] [Related]
40. Prevalence of ERG expression and PTEN loss in a Brazilian prostate cancer cohort.
Morais CE; Gurgel DC; Teixeira AC; Mattos TVA; Silva AVAD; Tavora F
Braz J Med Biol Res; 2019; 52(12):e8483. PubMed ID: 31826177
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
